Synendos Therapeutics

Unlocking the Mind’s Secrets: Synendos Therapeutics AG’s Journey to Transform Neuroscience Forever!

In the vast realm of neuroscience, where the complexities of the human brain continue to baffle researchers, Synendos Therapeutics AG emerges as a ray of hope. Pioneering a new era of neuroscience innovation, this dynamic company holds the promise of potentially breakthrough therapies for neuropsychiatric disorders. Led by the visionary Dr. Andrea Chicca, Synendos is trailblazing the path towards safe and effective treatments that could transform the lives of millions.

At the heart of Synendos’ journey lies the endocannabinoid system (ECS), a network of neurotransmitters and receptors in the brain that plays a crucial role in maintaining overall well-being. Leveraging cutting-edge science, the company focuses on the modulation of a novel drug target within the ECS, aiming to restore the natural functioning of the brain and alleviate the burden of neuropsychiatric conditions.


The ECS: A Gateway to Neurological Harmony

As a relatively unexplored frontier in neuroscience, the endocannabinoid system has captivated researchers with its potential therapeutic implications. Synendos’ lead drug candidate, SYT-510, marks a groundbreaking entry into this field as a Selective Endocannabinoid Re-uptake Inhibitor (SERI). This novel class of ECS modulators shows the promise of providing meaningful benefits to patients through a self-limiting mode of action.

Synendos recognizes the pressing unmet medical needs in anxiety and mood-related diseases, such as post-traumatic stress disorder (PTSD), which often arise from an endocannabinoid deficiency. By harnessing the potential of SYT-510, the company aims to address these disorders with a new approach that could revolutionize the treatment landscape.


The Science of Serenity: A Journey to Clinical Trials

With ambition and dedication, Synendos is marching steadily towards a clinical stage biotech status. The team anticipates SYT-510’s entry into crucial clinical studies during 2023, marking a significant milestone in the pursuit of groundbreaking therapies for neuropsychiatric disorders. This transition represents the culmination of years of rigorous research, relentless dedication, and unwavering belief in the potential of their innovative approach.


Funding the Future: A Strong Synergy of Support

In the challenging landscape of pharmaceutical development, funding plays a pivotal role in driving progress. Synendos secured a significant milestone by successfully closing a Series A round of CHF 24 million in April 2021. This remarkable achievement was made possible by a syndicate of esteemed investors, including Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, and Bernina BioInvest. The vote of confidence from these investors echoes the potential success of the company and the transformative impact of their therapeutic vision.

The journey doesn’t stop there. Synendos has also received CHF 4 million in grant funding from various sources, validating the technology, approach, and potential success of the company. This combined support empowers Synendos to forge ahead in its mission to uncover the secrets of the ECS and develop treatments that could change lives.


A Symphony of Minds: The University of Bern Connection

Synendos owes its roots to the University of Bern, where it first emerged as a promising spin-out. The company retains access to the extensive expertise of the ECS through its strong connection to the group of Prof Jürg Gertsch, who has been at the forefront of research in this field. This academic foundation serves as a bedrock for their scientific endeavors and fuels their drive to advance neuroscience for the betterment of humanity.

Patents: Safeguarding the Journey

In the fiercely competitive world of pharmaceuticals, protecting intellectual property is essential. Synendos has taken significant measures to secure its assets and targets by establishing a robust series of patents filed or granted in all major markets. This strategic move ensures that the company can continue to innovate and explore new frontiers in neuropsychiatric therapy, unhindered by potential imitators.

As Synendos Therapeutics AG continues to unravel the mysteries of the mind, the company stands poised to make a profound impact on the field of neuroscience. With a visionary team, groundbreaking research, and strong support from investors and academic partners, Synendos is at the forefront of the quest to develop safe and effective therapies for neuropsychiatric disorders. Their dedication to scientific excellence and commitment to transforming lives position them as a beacon of hope for those who suffer from these challenging conditions.